74746-36-4

Basic information

• Product Name: Urea, N-(2-chloroethyl)-N'-(4-cyclohexylphenyl)-
• CAS NO: 74746-36-4
• Molecular Formula: C15H21ClN2O
• Molecular Weight: 280.798
• Mol File: 74746-36-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Urea, N-(2-chloroethyl)-N'-(4-cyclohexylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Urea, N-(2-chloroethyl)-N'-(4-cyclohexylphenyl)-(74746-36-4)
• EPA Substance Registry System: Urea, N-(2-chloroethyl)-N'-(4-cyclohexylphenyl)-(74746-36-4)

Safety Data

• Hazardous Substances Data: 74746-36-4(Hazardous Substances Data)

Upstream product

• 1943-83-5 2-chloroethyl isothiocyanate 
• 6373-50-8 p-cyclohexylaniline 

Downstream Products

• 74746-30-8 C₁₅H₂₀N₂O 
• 1198227-42-7 C₁₅H₂₀N₂O 

Relevant articles and documents

Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors

A novel class of arylthiourea HCV inhibitors bearing various functionalities, such as cyclic urea, cyclic thiourea, urea, and thiourea, on the alkyl linker were designed and synthesized. Herein we report the synthesis and structure-activity relationships

HALOETHYL UREA COMPOUNDS AND THEIR USE TO ATTENUATE, INHIBIT OR PREVENT NON-CANCEROUS PATHOGENIC CELLULAR PROLIFERATION AND DISEASES ASSOCIATED THEREWITH

The present invention provides haloethyl urea compounds as described in Formula (I) and their use as anti-proliferative agent in the attenuation, inhibition, or prevention of non-cancerous cellular proliferation. These compounds are also provided for use as a therapeutic agent in the treatment of a disease or disorder, wherein pathogenesis of said disease or disorder is associated with non-cancerous pathogenic cellular proliferation.

Antimitotic antitumor agents: Synthesis, structure-activity relationships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents

A series of N-aryl-N′-(2-chloroethyl)ureas (CEUs) and derivatives were synthesized and evaluated for antiproliferative activity against a wide panel of tumor cell lines. Systematic structure-activity relationship (SAR) studies indicated that: (i) a branched alkyl chain or a halogen at the 4-position of the phenyl ring or a fluorenyl/indanyl group, (ii) an exocyclic urea function, and (iii) a N′-2-chloroethyl moiety were required to ensure significant cytotoxicity. Biological experiments, such as immunofluorescence microscopy, confirmed that these promising compounds alter the cytoskeleton by inducing microtubule depolymerization via selective alkylation of β-tubulin. Subsequent evaluations demonstrated that potent CEUs were weak alkylators, were non-DNA-damaging agents, and did not interact with the thiol function of either glutathione or glutathione reductase. Therefore, CEUs are part of a new class of antimitotic agents. Finally, among the series of CEUs evaluated, compounds 12, 15, 16, and 27 were selected for further in vivo trials.